BLIOGRAFIA - I Disordini Neurosensoriali nelle Encefalopatie Epilettiche: intervento riabilitativo nelle epilessie miocloniche severe (Sindrome di Dravet)

Ackermann H, Hertrich I. The contribution of the cerebellum to speech processing. J Neurolinguist 2000; 13: 95-116.
Aicardi J. Epilepsy in children (II edition). New York: Raven Press, 1994.
Akiyama M. Kobayashi K. Yoshinaga H, Ohtsuka Y. A long-term follow-up study of Dravet syndrome up to adulthood.
Epilepsia 2010; 51: 1043-52-
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts of the organization of seizures and epilepsies: Report of the ILAE commission on classification and terminology, 2005- Epilepsia 2010; 51: 676-85.
Brodie MJ, Schachter SC, Kwan P. Fast Facts: Epilessia. Fourth edition. Health Press Ltd. 2009
Buoni S, Orrico A, Galli L, et al. SCN1A novel truncating mutation with benign outcome of severe myoclonic epilepsy of infancy. Neurology, 2006; 66: 606.
Bureau M, Dalla Bernardina B. Electroencephalographic characteristics of Dravet Syndrome.
Epilepsia, 2011; 52 (Suppl. 2): 13-23.
Camfield P, Camfield C, Nolan K. Helping families cope with the devastation of Dravet syndrome.
European Journal of Paediatric Neurology 2012; 16: S9-S12.
Caraballo RH, Fejerman N. Dravet syndrome: A study of 53 patients. Epilepsy Res 2006; 70 (Suppl. 1): S231-8.
Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: Focus on the ketogenic diet.
Epilepsia, 2011; 52 (Suppl. 2): 79-82.
Cassé-Perrot C, Woff M, Dravet C. Neuropsychological aspects of severe myoclonic epilepsy in infancy. In: Jamaqué I, Lassonde M, Dulac O (eds). The Neuropsycology of childhood epilepsy. New- York: Plenum Press/Kluwer Accademic 2001; 131-40.
Castro-Gago M, Martinon Sanchez JM, Rodriguez-Nunez A, Herranz Fernandez JL. Eiris-Punal J. Severe Myoclonic epilepsy and mitochondrial cytopathy. Childs Nerv Syst 1997; 13: 570-1.
Catarino et al. Dravet syndrome as epileptic encelophaty: evidence from long-term course and neuropathology. Brain 2011.
Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: towards an optimal treatment. J Child Neurol 2004; 19: 516-21.
Chieffo D, Ricci D, Baranello G, Martinelli D, Veredice C, Lettori D, Battaglia D, Dravet C, Mercuri E, Guzzetta F. Early development in Dravet syndrome; visual function impairment precedes cognitive decline. Epilepsy Research 2010; 93: 73-9.
Chieffo D, Ricci D, Baranello G, et al. Early development in Dravet Syndrome; visual function impairment precedes cognitive decline. Epilepsy Res 2011a; 93: 73-9.
Chieffo D, Battaglia D, Lettori D, et al. Neuropsychological development in children with Dravet Syndrome. Epilepsy Res 2011b; 95: 86-93.
Chiron C, Dulac O. The pharmacologic treatment of Dravet Syndrome. Epilepsia 2011; 52 (Suppl. 2): 72-5.
Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 11: 356: 1638-42.
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68: 1327-32.
Coppola G, Capovilla G, Montagnini A, et al. Topiramate ad add-on drug in severe myoclonic epilepsy in infancy: An Italian multi center open trial. Epilepsy Res 2002; 49: 45-8.
Dalla Bernardina B, Capovilla G, Gattoni MB, Colamaria V, Bondavalli S, Bureau M. Èpilepsie myoclonique grave de la première année. Rev EEG Neurophysiol 1982; 12: 21-5.
Dalla Bernardina B, Capovilla G,Chiamenti C, Trevisan E, Colamaria V, Fontana E. Cryptogenic myoclonic epilepsies of infancy and early childhood: Nosological and prognostic approach. In: Wolf P, Dam M, Janz D, Dreifuss FE (eds). Advances in Epileptology. New-York: Raven Press, 1987: 175- 80.
Davidsson J, Collin A, Olsson ME, Lundgren J, Soller M. Deletion of the SCN gene cluster on 2q24.4 is associated with severe epilepsy: An array-based genotype-phenotype correlation and a comprehensive review of previously published cases. Epilepsy Res 2008; 81: 69-79.
Delogu AB, Spinelli A, Battaglia D, et al. Electrical and autonomic cardiac function in patients affected by Dravet syndrome. Epilepsia 2011; 52 (Suppl. 2): 55-8.
Depienne C, Arzimanoglou A, Trouillard O, et al. Parental mosaicism can cause recurrent transmission of SCN1A mutation associated with severe myoclonic epilepsy of infancy. Hum Mutat 2006; 27: 389.
Depienne C, Trouillard O, Gourfinkel-An I, et al. Mechanism for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet 2010; 47: 404-10.
Dibbens LM, Tarpey PS, Hynes K, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 2008; 40: 776-81.
Donner EJ, Smith CR, Snead OC. Sudden unexplained death in children with epilepsy. Neurology 2001; 57: 430-4.
Dravet C. Les epilepsies graves de l’enfant. Vie Med 1978; 8: 543-8.
Dravet C, Dalla Bernardina B, Mesdjian E, Galland MC, Roger J. Dyskinésies paroxystiques au cours des traitements par la diphénylhydantoine. Rev Neurol 1980; 136: 1-14.
Dravet C, Roger J, Bureau M, Dalla Bernardina B. Myoclonic epilepsies in childhood. In: Akimoto H, et al. (eds). Advances in Epileptology, the XIII EIS. New-York: Raven Press, 1982; 135-40.
Dravet C, Bureau M, Roger J. Severe myoclonic epilepsy in infancy. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey, 1985; 58-67.
Dravet C & Jallon P. Il bambino con epilessia. 2000 Editore Borla.
Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence (II edition). London: John Libbey, 1992a; 75-88.
Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet Syndrome). In: Roger J, Bureau M, Dravet C, Gelton P, Tassinari CA, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence (IV edition). Paris: John Libbey Eurotext, 2005a: 89-113.
Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet Syndrome. In: Delgado-Escueta AV, Guerrini R, Medina MT, Genton P, Bureau M, Dravet C (eds). Advances in Neurology. Vol. 95. Philadelphia: Lippinvcott Williams & Wilkins, 2005b: 71-102.
Dravet C, Daquin G, Battaglia D. Severe myoclonic epilepsy in infancy (Dravet Syndrome). In: Nikanorova M, Gelton P, Sabers A (eds). Long-term evolution of epileptic encephalopaties. Paris: John Libbey Eurotext, 2009: 29-38.
Dravet C. The core Dravet Syndrome phenotype. Epilepsia 2011; 52 (Suppl.2): 3-9
Dravet C, Guerrini R. Dravet Syndrome. Topics in Epilepsy. John Libbey Eurotext 2011.
Dravet C. Addressing the needs of patients and their family: Conclusion. European Journal of
Paediatric Neurology 2012; 16: S18-S20.
Dulac O, Arthuis M. L’épilepsie myoclonique sévère de l’enfant. In: Journées parisiennes de pédiatrie. Paris: Flammarion, 1982: 259-68.
Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium cannel in two famiglie with GEFS+2. Nat Genet 2000; 24: 343-5.
Fisher JL. The anticonvulsant stiripentol acts directly on the GABAa receptor as a positive allosteric modulator. Neuropharmacology 2009; 56: 190-7.
Fisher JL. Interactions between modulators of the GABAa receptor: Stiripentol and benzodiazepines.
Eur J Pharmaco 2011a; 2: 160-5.
Fisher JL. The effects of stiripentol on GABAa receptors, Epilepsia 2011b; 52 (Suppl. 2): 76-8. Fontana E, Dalla Bernardina B, Sgrò V, et al. Epilessia mioclonica severa (EMS) e/o Sindrome di
Dravet: Studio elettroclinico longitudinale di 53 soggetti. Boll Lega It Epil 2004; 125/126: 337-40.
Fujiwara T, Nakamura H, Watanabe M, et al. Clinicoelectrographic concordance between monozygotic twins with severe myoclonic epilepsy in infancy. Epilepsia 1990; 31: 281-6.
Fujiwara T, Watanabe M, Takahashi Y, et al. Long-term course if childhood epilepsy with intractable
Grand Mal seizures. Jpn J Psychiatr Neurol 1992; 46: 29.
Fujiwara T, Suguwara T, Mazaki-Miyazaki E, et al. Mutations of sodium canne alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003; 126: 531-46.
Fukuma G, Ognuni H, Shirasaka Y, et al. Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004; 45: 140-8.
Gastaut H, Broughton R, Tassinari CA. Unilateral epileptic seizures. In: Vinken PJ, Bruyn GW (eds). Handbook of Clinical Neurology: The Epilepsies, Vol XV. Amsterdam/New-York: Elsevier, 1974: 235-45.
Gennaro E, Santorelli FM, Bertini E, et al. Somatic and germiline mosaicism in Severe myoclonic epilepsy of infancy. Biochem Biophysl Res Commun 2006; 341: 489-93.
Genton P, Velizarova R, Dravet C. Dravet syndrome: The long-term outcome. Epilepsia 2011; 52 (Suppl. 2): 44-9.
Giobbi G, Giovanni S, Boni A, Visconti P, Beghi M, Cornaggia CM. Catatonic psychosis related to forced normalization in a girl with Dravet’s syndrome. Epileptic Disord 2008; 10: 125-9.
Giovanardi-Rossi PR, Santucci M, Gobbi G, Parmeggiani A, Pini A, Ambrosetto G. Long-term follow-up of severe myoclonic epilepsy in infancy. In: Fukuyama Y, Kamoshita S, Ohtsuka C, Susuki Y (eds). Modern perspectives of child neurology. Tokyo: Asahi Daily News, 1991: 205-13.
Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006; 34: 608-11.
Granata T. Comprehensive care of children with Dravet syndrome. Epilepsia 2011; 52 (Suppl. 2): 90- 4.
Grosso S, Galimberti D, Farnetani MA, et al. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 2005; 14: 183-9.
Grusser Cornehls U, Baurle J. Mutant mica as a model for cerebellar ataxia. Progr Neurobiol 2001; 63: 489-540.
Guerrini R, Falchi M. Dravet syndrome and SCN1A gene mutation related-epilepsies: Cognitive impairment and its determinants. Dev Med Child Neurol 2011; 53 (Suppl. 2): 11-5.
Guerrini R, Oguni H. Borderline Dravet syndrome: A useful diagnostic category? Epilepsia 2011a; 52 (Suppl. 2): 10-2.
Guerrini R, Pons G (eds). Comparative Study of the Efficacy of Stiripentol used in Combination in Severe Myoclonic Epilepsy of Infancy (SMEI). A Double-Blind, Multicenter, Placebo-Controlled Phase III Study. Calabrone (Pisa), Italy: Università di Pisa-IRCCS Stella Maris, 2000.
Guerrini R, Dravet C, Genton P, Bureau M, Bonanni P, Ferrari AR, Roger J. Idiopathic photosensitive occipital lobe epilepsy. Epilepsia 1995b; 36 (9): 883-91.
Guerrini R, Dravet C, Gelton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12.
Guerrini R, Tonnelier S, D’Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): A placebo-controlled trial. Epilepsia 2002; 43 (Suppl. 9): S155.
Guerrini R, Cellini E, Mei D, et al. Variable epilepsy phenotypes associated with a familiar intragenic deletion of SCN1A gene. Epilepsia 2010; 51: 2474-7.
Guerrini R, Striano P, Catarino C, Sisodiya SM. Neuroimaging and neuropathy of Dravet syndrome.
Epilepsia 2011b; 52 (Suppl. 2): 30-4.
Guerrini R. Dravet Syndrome: The main issues. European Journal of Paediatric Neurology 2012; 16: S1-S4.
Guzzetta F, Cioni G, Mercuri E, et al. Neurodevelopmental evolution of West syndrome: A 2-year prospective study. Eur J Paediatr Neurol 2008; 12: 387-97.
Harkin LA, Bowser DN, Dibbens LM, et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 2002; 70: 530-53.
Hattori J, Ouchida M, Ono J, et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 2008; 49: 626-33.
Hino-Fukuyo N, Haginoya K, Togashi N, et al. Ictal vomiting a san initial symptom of Severe myoclonic epilepsy in infancy: A case report. J Child Neurol 2009; 24: 228.
Horn CS, Ater SB, Hust DL. Carbamazepine-exacerbated epilepsy in children and adolescents.
Pediatr Neurol 1986; 2: 340-5.
Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia 1990; 31: 397-400. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res 2009; 85: 89-95.
Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet Syndrome. Epilepsia 2009; 50: 2362-8.
Jansen FE, Sadleir LG, Harkin LA, et al. Severe myoclonic epilepsy of infancy (Dravet syndrome): Recognition and diagnosis in adults. Neurology 2006; 67: 224-6.
Justus T, Ravizza SM, Fiez JA, Ivry RB. Reduced phonological similarity effects in patients with damage to the cerebellum. Brain Lang 2005; 95: 304-18.
Kalume F, Yu FH, Westenbroek RE, Scheure T, Catterall WA. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications of ataxia in severe myoclonic epilepsy in infancy. J Neurosci 2007; 27: 1165-74.
Kanazawa O. Medically intractable generalized tonic-clonic or clonic seizures in infancy. J Epil 1992; 5: 143-8.
Kanazawa O, Shirane S. Can early zonizamide medication improve the prognosis in the core and peripheral types of severe myoclonic epilepsy in infants? Brain Dev 1999; 21: 503.
Kassai C, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: A systematic review and meta-analysis of individual parent data. Epilepsia 2008; 49: 343-8.
Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr. Dravet syndrme (severe myoclonic epilepsy in infancy) A retrospective study of 16 patients. J Child Neurosl 2007; 22: 185-94.
Kossof EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50: 304-17.
Krishna-K K, Hertel N, Redies C. Cadherin expression in the somatosensory cortex: Evidence for a combinatorial molecular code at the single-cell level. Neuroscience 2011; 175: 37-48.
Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory parients with
Dravet syndrome. Neuropediatrics 2006; 37: 325-9.
Mangano S, Fontana A, Cusumano L. Begin myoclonic epilepsy in infancy: Neuropsychological and behavioral outcome. Brain Dev 2005; 27: 218-23.
Marini C, Mei D, Cross JH, Guerrini R. Mosaic SCN1A mutation in familial severe myoclonic epilepsy in infancy. Epilepsia 2006; 47: 1737-40.
Marini C, Mei D, Temudo T, et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia 2007; 48: 1678-96.
Martin MS, Dutt K, Papale LA, et al. Altered function of the SCN1A voltage-gated sodium canne leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Cherm 2010; 285: 9823-34.
McGregor A, Wheeless J. Pediatric experience with sudden unexplained death in epilepsy at the tertiary center. J Child Neurol 2006; 21: 782-7.
Mercuri E, Haataja L, Guzzetta A, et al. Visual function in term infants with hypoxic-ischemic insults correlation with neurodevelopment at 2 years of age. Arch Dis Child Fetal Neonatal Ed 1999; 80: F99-104.
Morimoto M, Mazaki E, Nishimura A, et al. SCN1A mutation mosaicism in a family with severe myoclonic epilepsy in infancy. Epilepsia 2006; 47: 1732-6.
Nabbout R, Gennaro E, Dalla Bernardina B, et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 2003; 60: 1961-7.
Nabbout R, Desguerre I, Sabbagh S, et al. An unexpected EEG course in Dravet syndrome. Epilepsy Res 2008; 81: 90-5.
Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: A prospective pilot study. Epilepsia 2011; 52: 54-7.
Nakayama T, Ogiwara I, Iti K, et al. Delections of SCN1A 5’ genomic region with promoter activity in Dravet syndrome. Hum Mutat 2010; 31: 820-9.
Nieto M, Roldan S, Sanchez B, et al. Estudio immunologico en pacientes con epilepsia mioclònica severa en la infancia. Rev Neurol (Spanish) 2000; 30: 1-15.
Nieto-Barrera M, Lillo MM, Rodriguez-Collado C, Candau R, Correa A. Epilepsia mioclonica grave de la infancia. Estudio epidemiologico analitico. Rev Neurol (Spanish) 2000a; 30: 620-4.
Nieto-Barrera M, Candau R, Nieto-Jimenez M, Candau R, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000b; 8: 590-4.
Ogino T, Ohtsuka Y, Tamatogi Y, et al. The epileptic syndrome sarin common characteristics during early childhood with severe myoclonic epilepsy in infancy. Jpn J Psychiatry Neurol 1989; 43: 479-81.
Ogiwara I, Miyamoto H, Morita N, et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: A circuit basis for epileptic seizures in mice carrying an SCN1A gene mutation. J Neursci 2007; 27: 5903-14.
Oguni H, Kitami H, Oguni M, et al. Treatment of severe myoclonic epilepsy in infants and its borderline variant with bromide. Epilepsia 1994; 35: 1140-5.
Oguni H, Hayashi K, Awaya Y, Fukuyama Y, Osawa M. Severe myoclonic epilepsy in infants – a rewiew based on the Tokyo Women’s medical university series of 84 cases. Brain Dev 2001; 23: 736- 48.
Oguni H, Hayashi K, Osawa M, et al. Severe myoclonic epilepsy in infants. Typical and borderline groups in relation to SCN1A mutations. In: Delgado-Escueta V, Guerrini R, Medina MT, Gelton P, Bureau M, Dravet C (eds). Advaces in Neurology, vol 95, Myoclonic Epilepsies. Philadelphia: Lippincott Williams & Wilkins, 2005: 103-11.
Ohki T, Watanabe K, Negoro K, et al. Severe myoclonic epilepsy in infancy: Evolution of seizures.
Seizure 1997; 6: 219-24.
Ohmori I, Ohtsuka Y, Murakami N, AsanoT, Hattori J, Oka E. Analysis of ictal EEG in Severe
Myoclonic Epilepsy in infancy. Epilepsia 2001; 42 (suppl 6): 54 (abstr).
Ohmori I, Ogtsuka Y, Ouchida M, Ogino T, Maniwa S, Shimizu K, Oka E. Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations? Brain Dev 2003; 27: 488-93.
Ohtsuka Y, Ohmori I, Ogino T, Ouchuida M, Shimizu K, Oka E. Paroxysmal movement disorders in severe myoclonic epilepsy in infancy. Brain Dev 2003; 25: 401-5.
Okumura A, Kurahashi H, Hirose S, et al. Focal epilepsy resulting from de novo SCN1A mutation.
Neuropediatrics 2007; 38: 253-6.
Patino GA, Claes LR, Lopez-Santiago LF, et al. A fuctional null mutation of SCN1B in a patient with
Dravet syndrome. J Neurosci 2009; 29: 2910764-78.
Pereira S, Vieira JP, Barroca F, et al. Severe epilepsy, retardation, and dysmorphic features with a 2q deletion including SCN1A and SCN2A. Neurology 2004; 63: 191-2.
Prunetti P, Perucca E. New and forthcoming antiepileptic drugs. Curr Opin Neurol 2011; 2: 159-64. Ragona F, Brazzo D, De Giorgi I, et al. Dravet syndrome: Early clinical manifestation and cognitive outcome in 37 Italian patients. Brain Dev 2010; 32: 71-7.
Ragona F, Granata T, Dalla Barnardina B, et al. Cognitive development in Dravet syndrome: A retrospective, multi center study of 26 patients. Epilepsia 2011; 52: 386-92.
Rodda JM, Scheffer IE, McMahom JM, Berkovic SF, Graham HK. Progressive Gait Deterioration in
Adolescents with Dravet Syndrome. Arch Neurol 2012; 69(7): 873-8.
Riva D, Vago C, Pantaleoni C, Bulgheroni S, Mantegazza M, Franceschetti S. Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes. Am J Med Genet Part A. 2009; 149a: 2339-45.
Saito Y, Oguni H, Awaya Y, Hayashi K, Osawa M. Phenytoin-induced choreoathetosis in patientis with severe myoclonic epilepsy in infancy. Neuropediatrics 2001; 32_ 231-5.
Sakauchi M, Oguni H, Kato I, et al. Mortality in Dravet syndrome: Search for risk factors in Japanase patients. Epilepsia 2011; 52 (Suppl. 2): 50-4.
Sarisjulis N, Gamboni B, Plouin P, Kaminska A, Dulac O. Diagnosis idiopathic/cryptogenic epilepsy syndromes in infancy. Arch Dis Child 2000; 82: 226-30.
Scheffer IE, Turner SJ, Dibbens LM, et al. Epilepsy and mental retardation limited to females: An under-recognized disorder. Brain 2008; 131: 918-27.
Scheffer IE. Diagnosis and long-term course of Dravet syndrome. European Journal of Paediatric Neurology 2012; 16: S5-S8.
Siegler Z, Barsi P, Neuwirth M, et al. Hippocampal sclerosis in seere myoclonic epilepsy in infancy: A retrospective MRI study. Epilepsia 2005; 46: 704-8.
Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: Extended spectrum of GEFS+? Epilepsia 2001; 42: 837-44.
Skluzacek JV, Watts KP, Parsy O, et al. Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 2011; 52 (Suppl. 2): 95-101.
Specchio N, Kasteleijn-Nost-Trenitè DGA, Piccioli M, et al. Diagnosing photosensitive epilepsy: Fancy new versus old fashioned techniques in patients with different epileptic sindrome. Brain Dev 2011; 33: 294-300.
Striano P, Mancardi MM, Biancheri R, et al. Brain MRI findings in severe myoclonic epilepsy in infancy and genotype-phenotype correlations. Epilepsia 2007a; 48: 1092-6.
Striano P, Coppola G, Pezella M, et al. An opel-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007b; 69: 922-5.
Suguma M, Oguni H, Fukuyama Y. Clinical and electroencephalographic study of severe myoclonic epilepsy in infancy (Dravet). Jpn J Psychiat Neurol 1987; 41: 463-5.
Suls A, Velizarova R, Yordanova I, et al.Four generations of epilepsy caused by an inherited microdeletion ofthe SCN1A gene. Neurology 2010; 75: 72-6.
Tanabè T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome): A nation-wide questionnaire survey in Japan. Brain Dev 2008; 30: 629-35.
Than TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tollerance of Stiripentol in severe myoclonic epilepsy of infancy (Dravet syndrome). Arch Pediatr 2002; 9: 1120-7.
Vadlamudi L, Dibbens LM, Lawrence KM, et al. Timing of the novo mutagenesis – a twin study of sodium-channel mutations. N Engl J Med 2010; 363: 1335-40.
Veggiotti P, Cardinalii S, Montalenti E, Gatti A, Lanzi G. Generalized epilepsy with febrile seizures plus and severe myoclonic epilepsy in infancy: A case report of two Italian families. Epileptic Disord 2001; 3: 29-32.
Villeneuve N, Portilla P, Ferrari AR, et al. Topiramate(TPM) in severe myoclonic epilepsy in infancy
(SMEI): Study of 27 patients. Epilepsia 2002; 43 (Suppl 8): 155.
Wakai S, Ito N, Sueoka H, et al. Severe myoclonic epilepsy in infancy and carbamazepine. Eur J Pediatr 1996b; 155: 724.
Wallace RH, Hodgson BL, Grinton BE, et al. Sodium channel alpha 1-subunit mutations in severe myoclonic epilepsy on infancy and infantile spasm. Neurology 2003; 61: 765-9.
Wang PJ, Fan PC, Lee WT, Young C, Huang CC, Shen YZ. Severe myoclonic epilepsy in infancy: evolution of electroencephalographic and clinical features. Acta Paed Sin 1996; 37: 428-32.
Wical B, Leighty D, Wendorf H, Tervo M, Tervo R, Maytum J. Signs of dysautonomia in children with Dravet syndrome (abstract). Epilepsia 2009; 50 (Suppl. 3): 164.
Yagi T, Takeichi M. Cadherin superfamily genes: Function, genomic organization, and neurologic diversity. Genes Dev 2000; 14: 1169-80.
Yakoub LM, Dulac O, Jambaqué I, Plouin P. Early diagnosis of severe myoclonic epilepsy in infancy.
Brain Dev 1992; 14: 299-303.
Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons un a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9: 1142-9.
Zaatreh M, Tennison M, D’Cruz O, Beach RL. Anticonvulsant-induced chorea: A role for pharmacodynamic drug interaction? Seizure 2001; 10: 596-9.
Zamponi N, Passamonti C, Cappanera S, Petrelli C. Clinical course of young patients with Dravet sindrome after vagal nerve stimulation. Eur J Ped Neurol 2010; 30: 1-7.

Indice

INTRODUZIONE

CONCLUSIONI

BLIOGRAFIA

Tesi di Laurea di: Francesca ORSINI

BLIOGRAFIA - I Disordini Neurosensoriali nelle Encefalopatie Epilettiche: intervento riabilitativo nelle epilessie miocloniche severe (Sindrome di Dravet)

Accedi / Crea il tuo account

Menu